journal article·2018-04-11Open access

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer

Zhimin Tao, Mandar Deepak Muzumdar, Alexandre Detappe, Xing Huang, Eric S. Xu, Yingjie Yu, Tarek H. Mouhieddine, Haiqin Song, Tyler Jacks, P. Peter Ghoroghchian

Nano Letters· Volume 18· Issue 4

Abstract

Human pancreatic ductal adenocarcinoma (PDAC) contains a distinctively dense stroma that limits the accessibility of anticancer drugs, contributing to its poor overall prognosis. Nanoparticles can enhance drug delivery and retention in pancreatic tumors and have been utilized clinically for their treatment. In preclinical studies, various mouse models differentially recapitulate the microenvironmental features of human PDAC. Here, we demonstrate that through utilization of different organic cosolvents and by doping of a homopolymer of poly(ε-caprolactone), a diblock copolymer composition of poly(ethylene oxide)- block-poly(ε-caprolactone) may be utilized to generate biodegradable and nanoscale micelles with different physical properties. Noninvasive optical imaging was employed to examine the pharmacology and biodistribution of these various nanoparticle formulations in both allografted and autochthonous mouse models of PDAC. In contrast to the results reported with transplanted tumors, spherical micelles as large as 300 nm in diameter were found to extravasate in the autochthonous model, reaching a distance of approximately 20 μm from the nearest tumor cell clusters. A lipophilic platinum(IV) prodrug of oxaliplatin was further able to achieve a ∼7-fold higher peak accumulation and a ∼50-fold increase in its retention half-life in pancreatic tumors when delivered with 100 nm long worm-like micelles as when compared to the free drug formulation of oxaliplatin. Through further engineering of nanoparticle properties, as well as by widespread adoption of the autochthonous tumor model for preclinical testing, future therapeutic formulations may further enhance the targeting and penetration of anticancer agents to improve survival outcomes in PDAC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pancreatic and Hepatic Oncology Research · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Koch Institute for Integrative Cancer Research at MIT, 500 Main Street, Cambridge, Massachusetts 02139, United States

Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, United States

Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, United States

Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510, United States

Funding

National Cancer Institute · National Center for Research Resources · Conquer Cancer Foundation · Charles W. and Jennifer C. Johnson Clinical Investigator Fund, Koch Institute for Integrative Cancer Research at MIT · Kathryn Fox Samway Foundation · Fondation Fran?aise de Recherche contre le My?lome et les Gammapathies · Misrock Foundation

References (60)

Show source-provided references
1. 10.3322/caac.2138710.3322/caac.21387 ↗
2. Ryan D. P. · N Engl J. Med. · 2014 · 371 · 2140
3. 10.1056/NEJMoa101192310.1056/NEJMoa1011923 ↗
4. 10.1056/NEJMoa130436910.1056/NEJMoa1304369 ↗
5. Rasheed Z. A. · 2012
6. 10.1136/gutjnl-2015-30930410.1136/gutjnl-2015-309304 ↗
7. 10.1158/1078-0432.CCR-11-311410.1158/1078-0432.CCR-11-3114 ↗
8. 10.1126/science.117136210.1126/science.1171362 ↗
9. 10.1016/j.ccr.2012.01.00710.1016/j.ccr.2012.01.007 ↗
10. 10.1136/gutjnl-2012-30252910.1136/gutjnl-2012-302529 ↗
11. 10.1158/1078-0432.CCR-15-201010.1158/1078-0432.CCR-15-2010 ↗
12. 10.1007/s11912-017-0608-310.1007/s11912-017-0608-3 ↗
13. 10.1146/annurev-physchem-040513-10371810.1146/annurev-physchem-040513-103718 ↗
14. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗
15. 10.1016/j.jconrel.2016.07.02110.1016/j.jconrel.2016.07.021 ↗
16. 10.1021/acs.nanolett.6b0505510.1021/acs.nanolett.6b05055 ↗
17. 10.1016/S0140-6736(15)00986-110.1016/S0140-6736(15)00986-1 ↗
18. 10.1021/nn404083m10.1021/nn404083m ↗
19. 10.1021/acsnano.5b0051010.1021/acsnano.5b00510 ↗
20. 10.1021/acsnano.5b0778110.1021/acsnano.5b07781 ↗
21. 10.1039/C1CS15258K10.1039/C1CS15258K ↗
22. 10.1021/ar200094a10.1021/ar200094a ↗
23. 10.1016/j.jconrel.2014.06.04210.1016/j.jconrel.2014.06.042 ↗
24. 10.1007/978-3-319-16555-4_1310.1007/978-3-319-16555-4_13 ↗
25. 10.1038/nrd450310.1038/nrd4503 ↗
26. 10.1002/wnan.133210.1002/wnan.1332 ↗
27. 10.1073/pnas.130134811010.1073/pnas.1301348110 ↗
28. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
29. 10.1021/nn500498t10.1021/nn500498t ↗
30. 10.1158/0008-5472.CAN-10-030310.1158/0008-5472.CAN-10-0303 ↗
31. 10.1021/acsnano.5b0201710.1021/acsnano.5b02017 ↗
32. 10.1016/S1535-6108(03)00309-X10.1016/S1535-6108(03)00309-X ↗
33. 10.1016/j.ccr.2005.04.02310.1016/j.ccr.2005.04.023 ↗
34. 10.1073/pnas.060127310310.1073/pnas.0601273103 ↗
35. 10.1016/j.jconrel.2017.05.02810.1016/j.jconrel.2017.05.028 ↗
36. 10.1021/ma051900910.1021/ma0519009 ↗
37. 10.1039/c3nr03250g10.1039/c3nr03250g ↗
38. 10.1016/j.ymeth.2008.05.00610.1016/j.ymeth.2008.05.006 ↗
39. 10.1016/j.biomaterials.2017.04.04610.1016/j.biomaterials.2017.04.046 ↗
40. 10.1007/s11095-007-9335-z10.1007/s11095-007-9335-z ↗
41. 10.1002/adma.20110319210.1002/adma.201103192 ↗
42. 10.1038/nature1416910.1038/nature14169 ↗
43. 10.1038/ncomms1268510.1038/ncomms12685 ↗
44. 10.1016/j.nano.2011.06.00910.1016/j.nano.2011.06.009 ↗
45. 10.1021/mp900022m10.1021/mp900022m ↗
46. 10.1016/j.ccr.2009.09.02710.1016/j.ccr.2009.09.027 ↗
47. Moghimi S. M. · Pharmacol Rev. · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
48. 10.1021/jacs.6b1210810.1021/jacs.6b12108 ↗
49. 10.1097/MPA.000000000000060710.1097/MPA.0000000000000607 ↗
50. 10.1021/acs.nanolett.5b0307310.1021/acs.nanolett.5b03073 ↗
51. 10.1371/journal.pmed.005008510.1371/journal.pmed.0050085 ↗
52. 10.1136/gutjnl-2016-31139310.1136/gutjnl-2016-311393 ↗
53. 10.1021/acsnano.6b0223110.1021/acsnano.6b02231 ↗
54. 10.1021/mp800051m10.1021/mp800051m ↗
55. 10.1038/nrclinonc.2016.11910.1038/nrclinonc.2016.119 ↗
56. 10.1039/C7BM00058H10.1039/C7BM00058H ↗
57. 10.1073/pnas.040939410210.1073/pnas.0409394102 ↗
58. 10.1021/ja055571b10.1021/ja055571b ↗
59. 10.1021/cm062427w10.1021/cm062427w ↗
60. 10.1039/b604212k10.1039/b604212k ↗